Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

108.44
+2.192.06%
Pre-market: 108.00-0.4400-0.41%09:16 EDT
Volume:1.71M
Turnover:184.58M
Market Cap:12.31B
PE:32.06
High:109.63
Open:106.66
Low:105.50
Close:106.25
52wk High:111.15
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:1.42
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:85.74
PE(LYR):42.36

Loading ...

Halozyme price target raised to $105 from $93 at Morgan Stanley

TIPRANKS
·
Aug 07

Halozyme Therapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07

Halozyme Therapeutics, Inc. : Leerink Partners Raises to Outperform from Market Perform; Raises Target Price to $110 from $83

THOMSON REUTERS
·
Aug 07

Halozyme Therapeutics, Inc. : Wells Fargo Raises Target Price to $95 from $75

THOMSON REUTERS
·
Aug 07

Morgan Stanley Adjusts PT on Halozyme Therapeutics to $105 From $93, Maintains Overweight Rating

MT Newswires Live
·
Aug 07

Movement Alert|Halozyme Therapeutics Rises 5.38% in Pre-Market Trading, Q2 Earnings Massively Beat Expectations with Full-Year Guidance Sharply Raised

Market Focus
·
Aug 07

Movement Alert|Halozyme Therapeutics Overnight Rise 6.08%, Q2 Earnings Significantly Beat Expectations with Full-Year Guidance Raised

Market Focus
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX) and Halozyme (HALO)

TIPRANKS
·
Aug 07

Stock Track | Halozyme Therapeutics Soars 5.39% in After-Hours Trading on Q2 Earnings Beat and Raised Guidance

Stock Track
·
Aug 07

Halozyme Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Halozyme Therapeutics Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

MT Newswires Live
·
Aug 07

Stock Track | Halozyme Therapeutics Soars 5.24% After-Hours on Q2 Earnings Beat and Raised 2026 Guidance

Stock Track
·
Aug 07

GUIDANCE: (HALO) Halozyme Therapeutics Now Expects 2026 Adjusted EPS Range $8.65-$9.00, vs. FactSet Est of $7.94

MT Newswires Live
·
Aug 07

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate

Benzinga Earnings
·
Aug 07

Halozyme Q2 FY26 GAAP Net Income Rises 39% to USD 229.9 Million; Revenue Increases 48% to USD 481 Million

Reuters
·
Aug 07

Halozyme Therapeutics Q2 Adjusted EPS USD 2.28 Vs. IBES Estimate USD 1.84

Reuters
·
Aug 07

Halozyme Therapeutics Outlook FY Adjusted EPS USD 8.65-9

THOMSON REUTERS
·
Aug 07

Earning Preview: Halozyme Therapeutics Q2 revenue is expected to increase by 42.52%, and institutional views are bullish

Earnings Agent
·
Jul 31

4% Undervalued? Halozyme Therapeutics (HALO) Nears Earnings At A Record High

Simply Wall St.
·
Jul 31